Instrument NameViking TheraInstrument Symbol(VKTX-Q)

Instrument ExchangeNASDAQ

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

Telemedicine once seemed like it was going to revolutionize healthcare.

Terns Pharmaceuticals just proved that it's competitive in the weight loss field.

Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

The company is looking especially good after some bad news coming from a rival.

An investment in these players today could score a big win down the road.

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up by +1.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +2.17%. Stocks on Wednesday recovered from early losses and settled higher, with...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.58%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.52%. After starting the day in the red, stocks have rebounded this afternoon....

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.60%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -1.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.19%. Stocks are under pressure today, with the Dow Jones Industrials falling...

The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.

Nvidia is heading for a 118% gain this year.

This business has solid results in hand, lots of cash, and more catalysts coming.

A monster rival is making aggressive moves in one particular segment.

The companies are chasing major innovations.

The new drugs this company is developing could be worth a lot more than the present market value of its stock.

The S&P 500 Index ($SPX ) (SPY ) today is down -0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.32%. US stocks today gave up an early advance and turned lower. Weakness in chip...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. US stocks today are slightly lower this morning, despite a decline in T-note yields....

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

Given this biotech's ascent, its odds of becoming a giant are better than most.

There isn't much to suggest these businesses are actually vulnerable.

Investing in these small caps could be rewarding in the long run.